|
|
November 2011
The StartUp Masterclass programme is offering the opportunity for early stage innovation-based ventures based in the East of England to participate in this special event on 28th November with support from the University's Centre for Entrepreneurial Learning (CfEL) and Cambridge AWiSE. Dr Madhuri Warren, will be one of the invited panel of successful entrepreneurs offering her personal story of success in the biotech sector as well as sharing her knowledge and expertise of how to develop a high growth company such as Pathology Diagnostics. For further information please visit the CfEL website. October 2011
Pathology Diagnostics Ltd. has been invited to present as a plenary speaker at the Oncology Networking Seminar. Dr. Madhuri Warren will highlight the company's achievements to date and inform delegates about
technological advances in
Image Analysis of Human Tissue in Drug and Biomarker Development. Dr. Madhuri Warren, Managing Director of Pathology Diagnostics Ltd. commented: "We are currently broadening our Image Analysis Portfolio in response to growing client demand for their preclinical and clinical projects, following our business development teams' efforts to increase our international awareness and clientele throughout Europe and the US". For further information please see the One Nucleus website http://www.onenucleus.com/onenucleus-events?id=599
September 2011
Pathology Diagnostics Ltd. has been invited to present at the European Technology showcase in Oncology Conference. Dr. Madhuri Warren will highlight the company's successes to date and inform delegates about the successful evaluation of predictive drug biomarkers in preclinical studies and clinical trials. The 3rd ECCP conference organised by Cancer Biosante and Oslo Cancer Cluster allows clinicans and researchers from major biopharmaceutical companies to accelerate innovation in cancer treatment. For further information please see the European Cancer Cluster website: www.ecc-partnering.com
June 2011
Dr. Madhuri Warren, Managing Director states: "We are committed to hiring the best staff and providing a supportive environment to train and develop their potential. The growth of our team reflects our expanding client portfolio and the business development activities of our management team and non-executive advisors".
May 2011
Presentation: "Evaluation of the Use of Immunohistochemistry to Identify Protein Biomarkers in Cancer Clinical Trials" “There is a growing interest in the evaluation of tissue based protein biomarkers in oncology clinical trials to determine drug efficacy and to identify surrogate endpoints and potential patient stratification markers. We have conducted an analysis of peer reviewed published full journal articles of oncology clinical trials over the time period 2005 to 2010 in which tissue based protein biomarkers were assessed by immunohistochemistry. We examine these findings in light of the critical factors required for successful evaluation of protein biomarkers in human clinical tissues and discuss the implications for successful clinical and analytical validation of biomarkers in general.”
For more details please see: Journal of Pathology, Volume 224, Issue S2, pages S1–S39
April 2011
Pathology Diagnostics Ltd is the only GCLP accredited laboratory in Cambridge providing tissue diagnostic services for industry clients after successfully passing a GCLP site inspection. The internationally recognised Good Clinical Laboratory Practice (GCLP) accreditation scheme monitors the performance of companies worldwide that perform laboratory testing on patient samples in clinical trials. As an accredited supplier, clients can be confident that the results generated by Pathology Diagnostics will be accurate, reliable and consistent and meets the specifications of independent auditors. CEO and Founder Dr. Madhuri Warren commented: “We are delighted to have achieved this recognition: GCLP accreditation provides our clients with peace of mind and confidence in our tissue diagnostic services for their clinical trials and adding value to their studies.” For more details, please see GCLP accreditation April 2011
The team of expert pathologists and scientists at Pathology Diagnostics Ltd. has recently shared 18 years of technical expertise with academic and industry scientists in a published review article in the internationally recognised journal ‘Biomarkers in Medicine: "There has been increased interest in the development of tissue based assays in biomarker development in recent years. Tissue based assays can add value and aid decision making in the early discovery stages of drug and biomarker development, as well as being developed for use as predictive biomarkers, and for patient stratification and prognostication in the clinic. The scientist must be aware of the legal and ethical issues related to the sourcing of human tissue samples. This review also discusses the limits of scope and critical aspects to success related to the use of the following tissue based methods: immunohistochemistry, tissue microarrays and automated image analysis. Future advances in standardisation of tissue biobanking methods, immunohistochemistry and quantitative image analysis techniques are also discussed." In Biomarkers in Medicine, Volume 5, number 2, April 2011, pp. 227-249 For further information please email: info@pathologydiagnostics.com
March 2011
Pathology Diagnostics Ltd. has been invited to present at the One Nucleus Gold Members Company Showcase presentation session. CEO, Dr. Madhuri Warren highlighted the companies successes to date and advised the audience of industry leaders of the importance of high quality samples and the role of accredited experts to perform tissue based testing in drug and biomarker development. “Pathology Diagnostics delivers high quality specialist tissue laboratory and diagnostic services to biotechnology, pharmaceutical and contract research organizations to support their development programmes for targeted therapeutics, tissue biomarkers and other companion diagnostics in oncology. From target identification to clinical trials, their experienced team of pathologists, scientists and associated laboratory professionals provides a unique breadth of scientific and medical consulting and diagnostics expertise.”
For further information please see the One Nucleus website www.onenucleus.com
January 2011
Dr. Madhuri Warren, Managing Director of Pathology Diagnostics Ltd. states: "The Coaching for High Growth programme is designed to help ambitious and forward thinking businesses unlock and sustain their high growth potential. In order to achieve this recognition, Pathology Diagnostics Ltd has passed a stringent selection process assessing its people and processes, quality management systems and all aspects of its business from finance to HR and business development". |
